Clik here to view.
Rhizen Pharmaceuticals AG宣布，RP7214治疗新冠肺炎患者2期研究进行首例患者给药
瑞士巴塞尔 (美国商业资讯)–专注于肿瘤和炎症的临床阶段生物制药公司Rhizen Pharmaceuticals...
View ArticleClik here to view.
Saladax Biomedical宣布Salvatore J. Salamone博士荣获著名的C.E. Pippenger博士奖
宾夕法尼亚州伯利恒 (美国商业资讯)–Salvatore J. Salamone博士在意大利罗马召开的国际治疗药物监测和临床毒理学会(IATDMCT) 2021年年会上荣获享有盛誉的C.E....
View ArticleClik here to view.
TAE Life Sciences Announces Installation of First Accelerator-based Neutron...
FOOTHILL RANCH, Calif. TAE Life Sciences (TLS), a biological-targeted radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced the successful...
View ArticleClik here to view.
Japan’s MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial...
TOKYO & BOTHELL, Wash. Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seagen Inc. (Nasdaq:SGEN) today announced that Japan’s Ministry of Health, Labour...
View ArticleClik here to view.
サラダックス・バイオメディカル、サルバトーレ・J・サラモネ博士が権威ある C.E. Pippenger博士賞を受賞したと発表
米ペンシルベニア州ベスレヘム （ビジネスワイヤ） — サルバトーレ・J・サラモネ博士が、イタリアのローマで開催された2021年国際治療薬物モニタリングおよび臨床毒物学会（IATDMCT）年次大会で、権威ある C.E....
View ArticleClik here to view.
米国ジャクソン研究所がチャールス・リバー日本法人の買収を発表
YOKOHAMA, Japan & FARMINGTON, Conn. 米国コネチカット州ファーミントンに本拠を置く、非営利の生物医学研究機関であるジャクソン研究所(JAX)は本日、日本チャールス・リバー株式会社のRMS（リサーチモデルサービス/Research Models and...
View ArticleClik here to view.
Anticancer Bioscience Welcomes New Investor into Seed Financing Round...
CHENGDU, China Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today that it had secured an additional CNY 68.4 million (~USD 10.6 million) from...
View ArticleClik here to view.
キャンサー・ディスカバリー誌に掲載のEXALT-1試験に関する論文で初のAI支援機能的精密医療プラットフォームががんの治療成績を改善することが証明
ウィーン & 英オックスフォード （ビジネスワイヤ） — エクセンシア（Nasdaq:...
View ArticleClik here to view.
Rhizen Pharmaceuticalsが局所進行性／転移性乳がん患者を対象としたテナリシブ (RP6530)の第2相試験における最初の患者への投与を発表
スイス・バーゼル （ビジネスワイヤ） — スイスに拠点を置いて腫瘍と炎症に特化した非公開の臨床段階バイオ製薬企業であるRhizen Pharmaceuticals...
View ArticleClik here to view.
Rhizen Pharmaceuticals AG宣布在Tenalisib (RP6530)治疗局部晚期或转移性乳腺癌的II期研究中首次向患者给药
瑞士巴塞尔 (美国商业资讯)–Rhizen Pharmaceuticals AG（简称Rhizen）总部位于瑞士，是一家私人控股的临床阶段生物制药公司，专注于肿瘤和炎症治疗药物。Rhizen今天宣布已开始在一项II期试验中给药，目的是评价Tenalisib（RP6530；具有额外SIK3活性的同工型选择性PI3K...
View ArticleClik here to view.
Merck and Eisai Receive Positive EU CHMP Opinions for KEYTRUDA®...
KENILWORTH, N.J. & TOKYO Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the Committee for Medicinal Products for Human Use (CHMP) of the...
View ArticleClik here to view.
Bio-Thera Solutions Expands Partnership with Pharmapark in Russia and other...
GUANGZHOU, China & MOSCOW Bio-Thera Solutions, Ltd. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and a pipeline of biosimilars, today...
View ArticleClik here to view.
Treadwell Therapeutics Announces Acquisition of TCRyption Inc., a Novel...
NEW YORK & HONG KONG Treadwell Therapeutics today announced the acquisition of TCRyption Inc., a company focusing on novel approaches to TCR based T cell therapy and a TIO Bioventures portfolio...
View ArticleClik here to view.
Treadwell Therapeutics宣布收购专注于新型TCR-T细胞疗法的TIO Bioventures投资组合公司TCRyption Inc.
纽约和香港 (美国商业资讯)–Treadwell Therapeutics今天宣布收购TCRyption Inc.，后者专注于新型TCR-T细胞疗法，是TIO...
View ArticleClik here to view.
BeiGene and Nanolek Announce Approval in Russia for BRUKINSA® (Zanubrutinib)...
CAMBRIDGE, Mass. & BEIJING & MOSCOW BeiGene (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve...
View ArticleClik here to view.
CDISC and REDCap Work Together to Foster More Meaningful Clinical Research...
AUSTIN, Texas & NASHVILLE, Tenn. CDISC has announced it will work with Research Electronic Data Capture (REDCap) on an initiative to pave the way for academic institutions and researchers to...
View ArticleClik here to view.
PharmaEssentia Announces Pipeline Presentation During Upcoming American...
BURLINGTON, Mass. PharmaEssentia Corporation (TPEx: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in...
View ArticleClik here to view.
Humanigen announces preparation of Phase 1b study of ifabotuzumab in solid...
BURLINGAME, Calif. Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company, today announced its research partners will present Phase 1 results from a study of ifabotuzumab in...
View ArticleClik here to view.
武田薬品工業: 2021年度上期は力強い業績を達成：グローバルブランド14製品の牽引により2021年度末まで成長の勢いが継続する見込み
大阪 （ビジネスワイヤ） — 武田薬品工業株式会社（TSE：4502/NYSE:TAK）は、本日、2021年度上期の業績を公表しましたのでお知らせします。上期の力強い業績に基づき、当社は2021年度通期のマネジメントガイダンスを維持します。 グローバルブランド...
View ArticleClik here to view.
Takeda Delivers Strong H1 FY2021 Results; Further Growth Momentum Expected...
OSAKA, Japan Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today announced financial results for the first half of fiscal year 2021 (period ended September 30, 2021). Based...
View Article